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ABSTRACT 
A transdominant mutant form of the rev gene, MIO, confers resistance to infection by the human inununo-
deficiency virus (HTV) in vitro and is currently under investigation as a potential intervention in acquired im-
munodeficiency syndrome (AIDS). In this report, w e examine three issues relevant to the safety of autologous 
transfer of h u m a n T cells genetically modified with Rev MIO. First, the potential for malignant transforma-
tion was assessed in vitro using interleukin-2 (IL-2) dependence and fibroblast transformation assays, and tu-
morigenicity was evaluated in severe combined immunodeficient (SCID) mice. Possible toxicity was evaluated 
by pathologic analysis following adoptive transfer of genetically modified h u m a n T cells into S C I D mice. 
Second, methods were developed that permit T cell activation required for gene transfer but do not allow 
replication of endogenous HIY. Third, T cell function was evaluated in peripheral blood lymphocytes (PBL) 
of HIY-seropositive donors transduced with Rev M I O and compared to a negative control mutant, A R e v M I O . 
By all criteria, no oncogenicity or toxicity was observed. H u m a n T cells transduced with these vectors did not 
grow in the absence of IL-2 in vitro, and no tumors were observed following transplantation of genetically 
modified h u m a n cells into recipient S C I D mice. Histopathological analysis of heart, lung, liver, spleen, and 
kidney of animals 1-21 weeks following adoptive transfer of gene-modified h u m a n T cells revealed no signif-
icant abnormalities. Additionally, no differences were observed in the pattern of cytokine secretion in enriched 
h u m a n P B L expressing Rev M I O compared to ARev M I O . These results suggest that h u m a n T cells geneti-
cally modified with Rev M I O or ARev M I O m a y be administered to patients vtith minimal toxicity. 
O V E R V I E W INTRODUCTION 
Expression of Rev MIO, a transdominant mutant form of "MJ ev is an essential trans-activator of human immuno-
the Rev gene, in T cell lines confers resistance to HIV in J\.deficiency virus (HIV) repUcation (Cullen, 1991; Greene, 
vitro. Insertion of this Rev M I O gene into P B L appears to 1991). This protein plays an important role in the ttansition 
be nontoxic and weU-tolerated by SCID mice. These results from early to late HIV-1 gene expression, resulting in matura-
demonstrate that genetic modification of T cells by an an- tion of the virus and vkion assembly. The description of mu-
tiviral gene can be performed safely and without overt tox- tant forms of Rev that inhibit vkal wild-type Rev activity 
icity. This finding encourages the development of thera- (MaUm and Cullen, 1991) led to the demonsttation that T cell 
peutic strategies to genetically protect T cells to prolong leukemia Unes stably ttansduced with a ttansdominant mutant 
their survival in HIV-infected individuals. form of Rev (Rev MIO) were protected from HIV infection in 
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vitro (MaUm et al, 1992). More recently, these observations 
have been extended to peripheral blood lymphocytes (PBL) fol-
lowing rettovkal ttansduction or particle-mediated gene ttans-
fer of vectors encoding Rev M I O or ARev MIO, together with 
the neomycin resistance gene (Woffendin et al, 1994). 
Furthermore, expression of this ttansdominant mutant form of 
Rev did not interfere with the immunological function of EL-
4 and Jurkat cell lines, as determined by mitogen-stimulated re-
lease of interieukin-2 (IL-2) (MaUm et al, 1992). 
To determine whether autologous transfer of such genetically 
modified cells was feasible, additional safety and toxicity stud-
ies were requked. In this study, we have evaluated the poten-
tial oncogenicity and toxicity of T cells geneticaUy modified 
with Rev MIO. W e find that these gene products exhibit no ac-
tivity in fibroblast ttansformation assays. ProUferation of Rev 
MIO- or ARev MlO-fransduced P B L remained exquisitely de-
pendent on exogenously suppUed IL-2, and adoptive transfer of 
Rev MIO- or ARev MlO-ttansduced human peripheral blood 
lymphocytes (PBL) into severe combined immunodeficient 
(SCID) mice failed to demonsttate any evidence of toxicity or 
pathology. These findings, together with the lack of cytokine 
secretion abnormalities or activation of endogenous HIV, sug-
gest that rettovkal or particle-mediated ttansfer of the c D N A 
encoding the Rev M I O gene into P B L is appropriate for further 
studies in humans to study survival of P B L ttansduced with Rev 
M I O or ARev MIO. These studies have implications for the de-
velopment of T cells that will be resistant to HIV infection and 
may help to preserve immunologic function in patients with ac-
quired immunodeficiency syndrome (AIDS). 
MATERIALS AND METHODS 
Media 
P B L cells were culttired in A I M V (GIBCO, Grand Island, 
N Y ) , X-Vivo 15 (Whitaker, Walkerville, M D ) , or human com-
plete medium ( H C M ) supplemented with antibiotics and 300 
IU IL-2/ml. C M consisted of RPMI-1640 (GIBCO) containing 
0.1 m M nonessential amino acids, 1 m M sodium pyruvate, 2 
m M L-glutamine, and 100 /xg/ml of gentamicin sulfate. This 
media was further supplemented with 1 0 % human A B serum 
(GIBCO), and 300 IU/ml rIL-2 (kindly provided by Chkon, 
Emeryville, CA). Transduced T cells were selected for expres-
sion of the Neo" gene by exposure to 300-400 pg/ml (active 
drug) of the neomycin analog G418 sulfate (Geneticin, 
GIBCO). Antirettoviral compounds (Delavkdine and CD4-
PE40) were kindly provided by The Upjohn Company 
(Kalamazoo, MI) and Boehringer Ingelheim Pharmaceuticals, 
Inc. (Nevkapine). 
Retroviral transduction of PBL 
PBL were isolated from heparinized blood by Ficoll-
Hypaque density gradient centrifugation, as previously de-
scribed (Woffendin et al, 1994). These cells were washed three 
times in Hanks' balanced salt solution (HBSS) and resuspended 
at 1 X 10* cells/ml in H C M or A I M V. P B L were plated into 
24-well tissue culture plates previously coated with anti-CD3 
(0KT3, 10 pg/ml in H B S S ovemight) or stimulated with 5 
pg/ml phytohemagglutinin (PHA) for up to 72 hr. Following 
stimulation, cells were infected for 6-12 hr with i/* Crip super-
natant of either pLJ Rev M I O or pLJ ARev M I O rettoviruses 
(Woffendin et al, 1994) with 5 pg/ml Polybrene. CeUs were 
incubated at a density of 1 X 10*/well in a 24-well plate con-
taining 1 ml of i/f Crip supematant and 1 ml of AIM-V medium 
and 300 IU of IL-2/ml. Following infection, cells were selected 
in A I M V medium containing 300 IU of IL-2/ml and 300 /ig/ml 
G418 (active). 
Particle-mediated gene transfer 
Plasmid DNA was Unearized by digestion with Aat n re-
striction enzyme, exttacted using phenol chloroform, precipi-
tated with ethanol, and resuspended in Tris-EDTA buffer p H 
8.0 to a final concenttation of 1 mg/ml. Microscopic gold par-
ticles (1.6 p m in diameter) were prepared. The plasmid D N A 
was coated onto the beads by precipitation with CaCl2 and sper-
midine, followed by ethanol washes. The ceUs were then ttans-
fected as previously described (Woffendin et al, 1994). A to-
tal of 800 ng of D N A was used to ttansduce 10 X 10* ceUs. 
Conditions for stimulation of P B L and G418 selection were as 
described for the rettovkal ttansduction procedures. 
Cell proliferation assays 
Ten million CD3-stimulated Rev MIO- or ARev MlO-mod-
ified P B L were washed twice in medium without IL-2 and re-
suspended at 5 X 10^ cells/ml in A I M V, supplemented with or 
without 300 IU of IL-2/ml. The number of viable cells present 
in the cultures was determined by trypan blue dye exclusion. 
When it was apparent by microscopic examination that aU the 
cells in these cultures without IL-2 were nonviable, the flasks 
were maintained for at least an additional 2 weeks to confum 
that no ttansformed cells grew out of the nonviable cultures. 
Adoptive transfer of Rev MIO/ARev 
MlO-transduced P B L 
SCID mice (Jackson Laboratories, Bar Harbor, ME) were 
housed in the SCID mouse facility at the University of Michigan 
under appropriate conditions. Mice received an i.v. and/or i.p. 
injection of 2 X IO'' to 3 X 10* P B L modified by rettoviral 
ttansduction or particle-mediated gene ttansfer and selected as 
described above. Following adoptive ttansfer, animals were ob-
served weekly for evidence of toxicity and were sacrificed at 
times specified. Animals were necropsied and examined for 
gross abnormaUties. Sections of heart, lung, liver, spleen, and 
kidney were recovered for histological examination. 
Cytokine analysis of transduced PBL 
IL-4 and granulocyte-macrophage colony-stimulating factor 
(GM-CSF) levels were measured using a standard ELISA pro-
tocol following manufacturers recommendations (Pharmingen). 
Cells (1 X 10* cells/ml) were plated in six-well plates that had 
been previously coated with or without immobiUzed OKT-3 (10 
/Ag/ml). Following incubation for 24 hr at 37°C, supematants 
were collected and assayed for cytokine levels. 
3Y1 Cell transformation assay 
Rat fibroblast cells (3Y1) growing in 10-cm-diameter tissue 
culture dishes were ttansduced witii (3 pg) linearized RSV/TAR 
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Rev MIO or RSV/TAR ARev MIO plasmids by particle-medi-
ated gene ttansfer or by infection with the R e v M I O or A R e v 
M I O rettovkal vectors (producer titers 10^-10* pfu/ml). T h e to-
tal n u m b e r of foci of cells representing ttansformed cells on 
each dish were counted microscopically 3 weeks post trans-
duction. A positive conttol for the ttansformation assay con-
sisted of 3 Y 1 ceUs that had been CaP04-ttansfected witii a 
y-src expression vector ( p Z A S 4, 3 p g ) . 
Quantitative PCR analysis 
To analyze gene ttansfer frequencies, limiting-dilution PCR 
was perfonned. Briefly, cells carrying Rev MIO or ARev MIO 
were diluted into C E M cells at progressively lower cell num-
bers. Chromosomal D N A was prepared from a total of 10' ceUs 
using a quick lysis method. The ceU pellet was suspended in 
10 m M KCl, 1 m M Tris-HCl pH 8.3, 0.25 m M M g C ^ (50 pl) 
and an equal volume of solution B (1 m M Tris-HCl pH 8.3, 
0.25 m M MgCl2, 0.1% Tween-20, 0.1% NP-40, and 50 mg/ml 
proteinase K). The reaction mixture was incubated at 56°C for 
1 hr and at 95°C for 20 min. The nucleotide sequences for Rev 
MIO and ARev MIO of the primers were chosen to match each 
vector uniquely as follows: sense primers (1) for pLJ Rev MIO 
(9335A), 5'-TCTTGTCTGCCAGATCCCGGATCCAT-3'; (2) 
for pLJARev MIO (311 IB), 5'-TTAAGTGACCAGCTACA-
GTCGGAA-3'; (3) for pRS V/TAR Rev M10 (3112B), 5' -GCT-
TAAGCTCATGGCAGGAA-3'; (4) for pRSV/TAR Rev MIO 
(3113B), 5' -GGAACCCAGTGCTTAAGCTTG-3'. A common 
antisense primer (3060B) 5'-CTCGTTACAATCAAGAGT-
TCTCAGATC-3' was used in all reactions. PCR detection of 
provttal D N A was standardized using serial dilutions of ACH-
2 cells in a total of IO' C E M cells; HTV proviral D N A was de-
tected using the gag-specific PCR primers SR38 and SR39. 
RESULTS 
Gene transfer does not alter proliferation of PBL 
Rev MIO, or the negative conttol, ARev MIO, was trans-
fened into PBL by either rettovkal vector or particle-mediated 
gene ttansfer. These cell suspensions were selected in G418, 
and a population of G418-resistant cells was recovered and ex-
panded as described previously (Woffendin et al, 1994). The 
percentage of ttansduced cells in the lymphocyte population, as 
estimated by limiting ceU dilution PCR using Rev MIO- and 
ARev MlO-specific primers, was found to be greater than 0.1% 
and 10% day 4 post-ttansduction for rettoviraUy and particle-
mediated gene ttansfer procedures, respectively. At day 22, the 
levels had increased to at least 2.5% for the rettovims and 25% 
for particle-mediated ttansduction procedures. VariabiUty was 
seen in the ttansduction frequencies between individual exper-
iments. In many subsequent experiments, ttansduction fre-
quencies obtained after transduction were much higher than for 
these particular experimental groups (Woffendin et al, 1994). 
The proliferation of anti-CD3-activated PBL populations con-
taining the Rev MIO or ARev MIO vectors was evaluated un-
der culture conditions in the presence or absence of IL-2. To 
demonsttate that ttansduction with Rev MIO does not interfere 
with regulation of T ceU growth, 1X10'' PBL were tested for 
IL-2 independent proliferation. In theory, such an assay could 
potentially detect a transformation event as rare as 1 in 10^ PBL. 
Cells ttansfected by retrovkal-mediated gene transfer with Rev 
MIO or ARev MIO were passaged for up to six culture cycles 
and proUferation was assessed (Fig. IA). PBL incubated with 
IL-2 continued to proliferate, although at a reduced rate as com-
pared to nonttansduced, unselected CD3-stimulated PBL (data 
not shown). However, when the anti-CD3-activated PBL were 
cultured in media devoid of their requisite growth factor, IL-2, 
they ceased proliferating and died rapidly. These cultures were 
maintained and followed for a minimum of 25 days to ensure 
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FIG. 1. IL-2 dependence of PBL genetically modified with 
Rev MIO or ARev MIO. Cells transduced by rettoviral or par-
ticle-mediated gene transfer were maintained in cell culture for 
22 days, washed twice in media without IL-2, and resuspended 
at a density of 5.0 X 10' cells/ml in the presence or absence of 
IL-2 (in fresh medium without G418 or antiviral agents). 
Growth was then monitored in the presence of IL-2 (Rev MIO, 
D; ARev MIO, O ) or after withdrawal of IL-2 (Rev MIO, O; 
ARev MIO, A ) and expressed as total cell numbers for the in-
dicated time periods after withdrawal of IL-2. Cultures were 
maintained at a cell density of 0.5-1.5 X 10* cells/ml. In the 
absence of IL-2, there was no increase in cell number in either 
rettovkally ttansduced (A) or particle-mediated transfected (B) 
cells. Cultittes were followed for 25 days in the absence of IL-
2. No viable cells were seen. 
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Table 1. Effect of Delavirdine or Nevirapine 
and CD4-PE40 ON Murine Amphotropic 
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Miuine amphottopic rettoviral pLJ-/3-Gal supematant (10"* 
G418 resistant colony forming units) produced from i/> Crip 
producer cells was inoculated onto 293 cells growing in 6-well 
plates. The wells contained 2 ml of medium with the indicated 
concenttations of antiviral compounds. After 3 days of incu-
bation, cells were fixed and stained for /3-Gal activity by X-
Gal staining, and the number of positive cells per duplicate well 
counted. Conttol unttansduced cells showed no X-Gal stain-
ing. 
Similar results were observed in PBL ttansduced by particle-
mediated gene ttansfer (Fig. IB). Cultures evaluated by a careful 
microscopic examination revealed that no viable cells remained. 
Specific inhibition of endogenous HFV activation with 
HIV-l antiviral agents 
The process of T cell stimulation, needed to promote opti-
mal gene ttansfer, can induce viral replication (Zagury et al, 
1986). To ttansduce and expand human PBLs derived from 
HIV-positive patients, activation of endogenous provims must 
thus be avoided. To address this problem, we developed con-
ditions for activation and expansion of lymphocytes that selec-
tively block productive HTV replication without affecting ttans-
duction. A nonnucleoside reverse transcriptase inhibitor was 
employed fliat specifically inhibits HIV-1 in vitro but does not 
affect murine rettoviral reverse transcription. Either of two dif-
ferent agents, delavirdine (U90152s) or nevirapine, were used. 
Both inhibitors noncompetitively bind to HIV-1 reverse ttan-
scriptase (Richman et al, 1991; Dueweke et al, 1993). They 
were used alone or in combination with a second antiviral, a 
chimeric toxin protein consisting of a C D 4 domain fused to 
Pseudomonas aeruginosa exotoxin (PE) A (CD4-PE40), which 
exerts its effect on cells akeady infected with HIV (Chaudhary 
et al, 1988). 
To determine whether a nonnucleoside reverse ttanscriptase 
inhibitor and CD4-PE40 could inhibk HIV repUcation in vitro 
and not interfere with ttansduction by the vector, we infected 
the human renal epitheUal cell, 293, with a murine amphottopic 
rettovkal vector encoding /3-galactosidase at an moi of 0.1 in 
the presence or absence of tiiese agents (Table 1). Eidier delavir-
dine or nevkapine, alone or in combination with CD4-PE40 
showed minimal inhibition of murine rettoviral transduction. In 
conttast, azidothymidine (AZT), which is not HIV-l selective, 
inhibited ttansduction by the murine rettovkal vector (Table 1). 
Delavirdine or nevkapine alone or in combination with CD4-
PE40, however, effectively suppressed HIV repUcation to un-
detectable R T levels in freshly infected lymphocyte cultures 
over a 3-week period (Grob et al, 1992; Skoog et al, 1992; 
Vasudevachari et al, 1992; data not shown). 
To evaluate the efficacy in patient cells in vitro, lymphocytes 
from an asymptomatic HIV+ patient (CD4+ count -400) were 
activated in the presence of these dmgs. Provkal HIV D N A 
content was determined by limiting dilution PCR for 22 days 
post-stimulation. A significant reduction in lymphocyte provi-
ral D N A content was observed in antivkal tteated cultures 
compared to untteated cells. Before tteatment, between 
1:250-1:2,500 cells were HIV-positive using gag-specific 
primers. After tteatment for 8 days, —1:25,000 were positive 
with nevkapine/CD4-PE40 and fewer than 1:50,000 (flie limit 
of our PCR detection system) with delavirdine/CD4-PE40 tteat-
ment (data not shown). No p24 antigen (less than the detection 
limit of ~ 2 pg/ml p24) or reverse transcriptase activity above 
baseline was detected in culture supematants over a culture pe-
riod of 22 days. Thus, these agents were effective in reducing 
HIV activation in cell culture without interfering with the 
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"Lymphopenia noted, due to immunodeficient condition of SCID mice. 
''Heart: Focal epicardial fibrosis/calcification (minor pathological changes of no clinical significance). 
•̂ Lung: Peribronchial lymphoid aggregates (minor pathological changes of no clinical significance). 
''Heart: Focal epicardial calcification (minor pathological changes of no clinical significance). 
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murine retroviral vector. Similarly, these agents had no major 
effect on gene transfer efficiencies by particle-mediated gene 
transfer. 
PBL transduced with Rev MIO or ARev MIO fail to 
form tumors and show a lack of toxicity in SCID mice 
Next, we sought to determine whether transduced T cells 
could be administered to SCID mice without signs of overt tox-
icity. Eight mice received 1-3 X 10* PBL transduced with 
retroviral vectors for either Rev MIO or ARev MIO. Following 
adoptive transfer of T cells, mice were observed several times 
each week and appeared healthy at times ranging from 18 to 
60 days post infusion. On gross examination at necropsy, all 
animals appeared normal, with no evidence of overt malig-
nancy. To determine whether toxicity was observed in major 
organs following adoptive transfer of these modified T cells, 
histological analysis ofthe heart, lung, liver, kidney, and spleen 
was performed on tissues obtained from the sacrificed animals. 
No significant immune or inflammatory changes from the un-
derlying immunodeficiency, or cytopathology was observed in 
6 animals that underwent pathologic analysis (Table 2). These 
data suggest that up to 3 X 10* PBL transduced with Rev MIO 
or ARev M I O could be adoptively transferred into SCID mice 
without deleterious effects. 
PBL modified by particle-mediated Rev MIO gene 
transfer show a lack of oncogenicity or toxicity in 
SCID mice 
Six SCID mice received adoptive transfer of 2-A X 10'' PBL 
transfected by particle-mediated gene transfer. Mice were sac-
rificed at 1, 2, 3, and 21 weeks following adoptive transfer. 
Similar to the recipients of transduced PBL, no evidence of tox-
icity was observed in any animal (Table 3). Gross examination 
of these animals failed to reveal abnormalities and no major ev-
idence of cytopathology, immune, or inflammatory changes was 
observed in any animal. This second set of experiments main-
tained 3 animals for 21 weeks to evaluate the safety of PBL 
modified by particle-mediated Rev MIO gene transfer over a 
longer time period. 
Transformation assays 
The potential for malignant transformation was assessed fur-
ther in vitro by a fibroblast transformation assay. Cells (3Y1) 
were transduced with RSV/TAR Rev MIO or RSV/TAR ARev 
MIO plasmids using particle-mediated gene transfer or by in-
fection with the Rev MIO or ARev MIO retroviral vectors. 
Following transduction, cells were grown for 3 weeks after 
which foci representing transformed cells were counted micro-
scopically. No foci were seen in any Rev MIO- or ARev MlO-
transduced cells. In contrast, positive controls consisting of 3Y1 
cells transfected with ZAS 4, a \-src expression vector, gave 
208 foci. 
Toxicity of DNA-coated gold particles 
A safety consideration that is unique to particle-mediated 
gene delivery is the potential for injection of gold particles into 
patients. This possibility is unlikely, because the particles are 
removed by low-speed centrifugation on human serum albumen 
prior to reinfusion of transduced cells; however, the general 
question of toxicity of plasmid gold particles in humans was 
discussed. To address this question, DNA-coated gold particles 
were tested in 6- to 8-week-old BALB/c female mice to deter-
mine their potential for toxicity. Gold particles coated with 
RSV/Rev MIO plasmid were injected intravenously (8 mice) 
and a negative control group received normal saline (8 mice). 
The test group was injected with 0.8 pg of D N A and 500 m g 
of gold microspheres (1,000X greater than are Ukely to be in-
advertendy administered to patients). After 10 days, the recip-
ients were sacrificed, and the organs were removed and exam-
ined both grossly and histologically. Serum samples were 
obtained prior to injection, and at the time recipient animals 
were sacrificed and were analyzed for evidence of alterations 
in selected serum enzymes and chemistries. These studies have 
failed to demonstrate any signs of toxicity (Table 4). 
IL-4 and GM-CSF cytokine production in Rev MIO-
and ARev MlO-transduced P B L stimulated with anti-
C D S antibody 
To see whether expression of Rev MIO could alter cytokine 
production in transduced PBL populations, PBL obtained from 
an asymptomatic HIV seropositive donor were transduced with 
linearized RSV/TAR Rev M I O or RSV/TAR ARev M I O plas-
mids by particle-mediated gene transfer or by infection with the 
Rev M I O or ARev MIO retroviral vectors as described previ-
ously (Woffendin et al, 1994). Following transduction, cells 
were selected in G418 (300 pg/ml active) for up to 3 weeks. 











































































"Lymphopenia noted, due to immunodeficient condition of SCID mice. 
''Lung: Peribronchial lymphoid aggregates (minor pathological changes of no clinical significance). 
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The following are incidental findings of no pathological significance. 
1. Focal cluster of mononuclear inflammatory cells 
2. Focal calcification of epicardium 
3. Focal peribronchial lymphoid aggregates 
4. Minimal focal very recent tubular necrosis 
5. Focal endobronchial cluster of foamy macrophages. Focal peribronchial lymphoid aggregates. Focal interstitial macrophage 
clusters with particulate inclusions. 
The capacity of these transduced cells to respond to an im-
munological stimulus was tested by culturing cells with immo-
biUzed anti-OKT3. Culturing cells under these conditions, 
which cross-Unks the T cell receptor (TCR), is thought to mimic 
immunologic recognition of antigen by the TCR, resulting in T 
cell proliferation and cytokine release. For each experiment, 
control T cell populations were cultured in C M without being 
exposed to immobilized anti-OKT3. Cytokine release by 
OKT3-stimulated T cells was divided by cytokine released by 
control nonstimulated T cells and plotted as fold stimulation 
(Fig. 2). Cytokine release assays were performed at intervals 
throughout the experiment. No significant differences in the 
fold stimulation in IL-4 and GM-CSF levels from PBL were 
noted either by retroviral or particle-mediated gene transfer 
(Fig. 2). During this experiment, antiviral agents delavirdine (5 
pUf) and CD4-PE-40 (4 nM) were supplemented in the medium 
to prevent any possible spread of HFV infection during the stim-
ulation procedures. PCR analysis of PBLs for HIV proviral copy 
number using ̂ag-specific primers showed less than 1 in 25,000 
cells were infected throughout the experiment; no p24 antigen 
could be detected in the culture supematants (data not shown). 
D I S C U S S I O N 
In this study, three questions have been addressed that are 
relevant to the application of gene transfer technology for the 
treatment of individuals infected with HIV. First, the effect of 
Rev MIO or ARev MIO on human lymphocyte proliferation was 
analyzed. Second, methods were developed to suppress HIV 
repUcation in activated T cells from seropositive donors. 
Finally, the possible toxicity of Rev M10 gene expression in 
these cells was analyzed in vitro and in immunosuppressed an-
imals. W e have found no evidence of abnormal growth prop-
erties, toxicity or tissue pathology in this model. Endogenous 
HIV repUcation was suppressed, despite effective T cell acti-
vation. These findings suggest that transfer of Rev M10 or ARev 
MIO vectors provide no readily apparent contraindications to 
use in humans. 
Although previous cUnical trials using retroviral vectors to 
integrate constructs into PBL failed to demonstrate acute toxi-
cities, it was important to ascertain whether integration and ex-
pression of the ti-ansdominant negative Rev protein could af-
fect lymphocyte proliferation or function. Previous studies 
demonstrated that constitutive Rev MIO expression did not in-
terfere with mitogen-induced IL-2 secretion by murine or hu-
man T cell lines (MaUm et al, 1992). However, because these 
T cell lines normally exhibit unregulated growth in vitro, the 
effect of Rev MIO or ARev MIO expression on cell growtii 
could not be evaluated. Therefore, normal PBL were targeted 
for ti-ansfer of the Rev MIO or ARev MIO constiucts and ex-
amined for alterations in cell growth. Results of these studies 
find no evidence tiiat transfer of die Rev MIO or ARev MIO 
gene into PBL may lead to a malignant ttansformation. To test 
the potential of these gene-modified ceUs to exhibit a malig-
nant transformation in vivo, PBL were infused into SCID mice. 
The SCID mouse offers an opportunity to grow and study 
human cells in an in vivo environment (Mosier et al, 1991). 
Long-term engraftment of SCID mice with human peripheral 
blood lymphocytes has been somewhat conti-oversial. On the 
other hand, short-term survival of human T cells is believed 
to be not problematic in this model (Mosier et al, 1991). 
Therefore, we have used this animal model to address safety 
issues relevant to the expression of Rev MIO tiansduced PBL 
ANALYSIS OF HUMAN LYMPHOCYTES WITH A TRANSDOMINANT MUTANT REV GENE 
A. Particle-mediated Gene Transfer 
GM-CSF IL-4 
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FIG. 2. Cytokine production of Rev MIO or ARev MIO ttansduced PBL following stimulation with anti-CD3 antibody. Cells 
were ttansduced with Unearized RSV/TAR Rev MIO or RSV/TAR ARev MIO plasmids by particle-mediated gene ttansfer (A) 
or by rettoviral infection with the R e v M I O or A R e v M I O rettoviral vectors (B). After selection in G 4 1 8 for 12 days, IL-4 and 
G M - C S F cytokine levels in P B L culture supematants were determined in the presence or absence of immobilized O K T - 3 anti-
body by E L I S A . Fold stimulation in cytokine levels induced by treatment with O K T - 3 for 2 4 hr are shown. 
in S C I D mice. These experiments examined animals that re-
ceived infusions of 2 X 10^-3 X 10* ttansduced or conttol non-
ttansduced P B L . N o acute toxicity w a s observed in any animal 
following adoptive ttansfer of R e v M I O P B L . Similarly, w e 
failed to detect evidence of toxicity, malignant ttansformation, 
or major cytopathology associated with the infusion or abnor-
mal cytokine secretion pattems in R e v M I O P B L up to 21 
weeks. These data suggest that using rettoviral or particle-me-
diated gene ttansfer, the rev M I O gene can be expressed in P B L 
and safely admimstered in humans. 
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